Inhibition of Skeletal Formation in the Chick Embryo following Administration of Tetracycline

Bevelander, Gerrit; Nakahara, Hiroyuki; Rolle, Gloria K.

doi:10.1038/184728b0

Cited by 52 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ces marqueurs vitaux sont détectables, sur des prépara-tions histologiques non décalcifiées, par la fluorescence qu'ils émettent lorsqu'ils sont irradiés en lumière ultra-violette (microscopie de fluorescence). L'utilisation de l'une de ces substances ou la combinaison de plusieurs d'entre elles ont permis d'étudier avec succès la dynamique du tissu osseux chez les Mammifères (voir en particulier Dupont, 1964 ;Dhem, 1967 ;Skinner et Nalbandian, 1975 (Lopez, 1970 ;Simmons et al,1970 ;Meunier, 1972Meunier, et 1974 Boivin, 1972Boivin, et 1974 (Solheim, 1974 ;Vilmann, 1974 ;Rasmussen, 1975 (Bevelander et al, 1959) et chez les rats embryonnaires ou nouveaux-nés (Bevelander, 1964 ;Marois et Marois, 1971 …”

unclassified

Action de la fluorescéine, de l'alizarine, du bleu de calcéine et de diverses doses de tétracycline sur la croissance de la truite et de la carpe

Meunier¹,

Boivin²

1978

Ann. Biol. anim. Bioch. Biophys.

View full text Add to dashboard Cite

show abstract

unclassified

Action de la fluorescéine, de l'alizarine, du bleu de calcéine et de diverses doses de tétracycline sur la croissance de la truite et de la carpe

Meunier¹,

Boivin²

1978

Ann. Biol. anim. Bioch. Biophys.

View full text Add to dashboard Cite

show abstract

“…The partial or total coating dissolution that occurred in-vivo was possibly related to the low thicknesses thin-film coated implants and/or its microstructural phase composition 15,30 . The presence of fluorescent labels at regions in proximity and away from the implant surface in all specimens demonstrated the effectiveness of oxytetracycline as a tissue marker 4,6,13,16,[23][24]26 , enabling quantification of relative degrees of bone activity around the implants 10,14,27 at both times invivo.…”

Section: Discussionmentioning

confidence: 99%

“…A bone tissue marker is defined as any identifiable feature, naturally occurring or artificially induced, which permits the location of a given bone surface in anatomical space at a known moment in time 26 . The use of tetracycline (TC) as a tissue marker was introduced [23][24] , reviewed 4,13 and has been recently applied 6.16 due to its fluorescent properties, which allow for determination of osteoblastic activity (osseoactivity) in nondecalcified specimens. TC use has been extensive as a bone research tool regarding location and kinetics of bone formation and growth.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of an IBAD thin-film process as an alternative method for surface incorporation of bioceramics on dental implants: a study in dogs

Coelho

Suzuki

2005

J. Appl. Oral Sci.

View full text Add to dashboard Cite

hin-film bioceramic coatings are potential alternatives to overcome the limitations provided by other commercially available coating techniques like PSHA, where variable bioceramic dissolution added to a metalloceramic weak link are process-inherent. The purpose of this investigation was to determine the overall and site specific (to 0.5 mm from implant surface) levels of osseoactivity around a thin-film (IBAD processed) coated titanium alloy implant versus a non surface modified (sand-blasted/acid etched) titanium alloy implant in a canine model. The surgical model comprised the proximal tibiae epiphyses with four implants placed in each limb remaining for 2 and 4 weeks in-vivo. 10 mg/Kg oxytetracycline was administered 48 hours prior to euthanization. The limbs were retrieved by sharp dissection, reduced to blocks, and subsequently nondecalcified processed for fluorescent microscopy. Micrographs (20x mag) were acquired around the implant perimeter and merged for overall biological response evaluations, and four micrographs (40x mag. subdivided in rectangles) were acquired along one of the implant sides for tetracycline labeled area fraction quantification. The results showed biocompatible and osseoconductive properties for the thin-film coated and uncoated titanium alloy implants. Tetracycline labeled area fraction analyses showed that the thin-film coated implants presented significantly higher overall and site specific osseoactivity levels at 2 and 4 weeks. The site specific osseoactivity values were significantly higher compared to overall values for control and thinfilm coated implants at both times in-vivo. According to the results obtained in this study, thin-film coated implants enhanced biological response at the early implantation times evaluated. Uniterms: Dental implants; Thin-film coatings; Osseointegration; Tetracycline labeling; Bioceramic; Histomorphometry measurements; Dogs. ecobrimentos biocerâmicos de baixa espessura são potenciais alternativas para compensar as limitações de outros recobrimentos biocerâmicos disponíveis comercialmente como o plasma spray de hidroxiapatita, onde a dissolução desigual e a presença de uma fraca interface metal-cerâmica são problemas inerentes ao seu processamento. O propósito desta investigação foi determinar os níveis de atividade óssea total e específica a uma área (0.5 mm da superfície do implante) ao redor de um implante de liga de titânio (superficie jateada seguida de ataque ácido) recoberto com um filme biocerâmico de baixa espessura processado através de deposição auxiliada por feixe iônico, contra um implante de liga de titânio sem recobrimento biocerâmico em cães. O modelo cirúrgico utilizou a epífise proximal da tibia, com quatro implantes colocados em cada uma, onde permaneceram por um período de 2 e 4 semanas. Oxitetraciclina (10 mg/Kg) foi administrada 48 horas antes dos animais serem sacrificados. As tíbias foram dissecadas, reduzidas a blocos, e processadas para análise em microscópio ótico. Microfotografias com aumento de 20x foram obtidas da r...

show abstract

“…Its usage was discontinued in pediatric medicine as the high affinity to HAp caused children's teeth to stain yellow [25]. Furthermore, other early studies found that tetracycline may inhibit skeletal growth in children [26,27]. Its use as an antibiotic in adults and a targeting ligand in bone disease though, has not persisted.…”

Section: Targetingmentioning

confidence: 99%

Targeting polymer therapeutics to bone

Low

Kopeček

2012

Advanced Drug Delivery Reviews

136

View full text Add to dashboard Cite

An aging population in the developing world has led to an increase in musculoskeletal diseases such as osteoporosis and bone metastases. Left untreated many bone diseases cause debilitating pain and in the case of cancer, death. Many potential drugs are effective in treating diseases but result in side effects preventing their efficacy in the clinic. Bone, however, provides an unique environment of inorganic solids, which can be exploited in order to effectively target drugs to diseased tissue. By integration of bone targeting moieties to drug-carrying water-soluble polymers, the payload to diseased area can be increased while side effects decreased. The realization of clinically relevant bone targeted polymer therapeutics depends on (1) understanding bone targeting moiety interactions, (2) development of controlled drug delivery systems, as well as (3) understanding drug interactions. The latter makes it possible to develop bone targeted synergistic drug delivery systems.

show abstract

Inhibition of Skeletal Formation in the Chick Embryo following Administration of Tetracycline

Cited by 52 publications

References 3 publications

Action de la fluorescéine, de l'alizarine, du bleu de calcéine et de diverses doses de tétracycline sur la croissance de la truite et de la carpe

Action de la fluorescéine, de l'alizarine, du bleu de calcéine et de diverses doses de tétracycline sur la croissance de la truite et de la carpe

Evaluation of an IBAD thin-film process as an alternative method for surface incorporation of bioceramics on dental implants: a study in dogs

Targeting polymer therapeutics to bone

Contact Info

Product

Resources

About